DuoHexaBody-CD37 (GEN3009)

DuoHexaBody®-CD37 (GEN3009) is a bispecific IgG1 antibody created with Genmab’s proprietary DuoHexaBody technology platform. The DuoHexaBody platform combines the dual targeting of our DuoBody technology with the enhanced potency of our HexaBody technology, creating bispecific antibodies with target-mediated enhanced hexamerization. In preclinical settings, DuoHexaBody-CD37 has been shown to induce potent in vivo and in vitro anti-tumor activity.

Clinical studies
A Phase I clinical study of DuoHexaBody-CD37 in hematological malignancies is ongoing.